摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[3-(3-benzyl-5-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl)propyl]-4-orthotolylpiperidine-4-carbonitrile | 270077-68-4

中文名称
——
中文别名
——
英文名称
1-[3-(3-benzyl-5-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl)propyl]-4-orthotolylpiperidine-4-carbonitrile
英文别名
1-[3-(3-Benzyl-5-methyl-2,6-dioxopyrimidin-1-yl)propyl]-4-(2-methylphenyl)piperidine-4-carbonitrile
1-[3-(3-benzyl-5-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl)propyl]-4-orthotolylpiperidine-4-carbonitrile化学式
CAS
270077-68-4
化学式
C28H32N4O2
mdl
——
分子量
456.588
InChiKey
BNHLIZUTZOIETE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    34
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.39
  • 拓扑面积:
    67.6
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • US6232318B1
    申请人:——
    公开号:US6232318B1
    公开(公告)日:2001-05-15
  • [EN] PYRIMIDINEDIONE DERIVATIVES USEFUL AS ALPHA 1A ADRENOCEPTOR ANTAGONISTS<br/>[FR] DERIVES DE LA PYRIMIDINEDIONE, ANTAGONISTES DE L'ADRENOCEPTEUR ALPHA 1A
    申请人:MERCK & CO INC
    公开号:WO2000029386A1
    公开(公告)日:2000-05-25
    Novel pyrimidinedione compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.
查看更多